AI-based Measurements of Tumour Burden in PSMA PET-CT
Recruiting · NCT06363435 · Observational (researchers observe without assigning treatment) · Lead sponsor: Elin Tragardh
View the official record on ClinicalTrials.gov →Interventions studied
AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
What this trial is about
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).
Who can take part
Age range
20 Years to 120 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden
Exclusion criteria
- Patients under 20 years old
Where it is running
2 locations listed.
- Skåne University Hospital - Lund, Sweden
- Skåne university hospital - Malmö, Sweden